Recombinant factor VIIa (rFVIIa, NovoSeven) is FDAapproved for the treatment of bleeding in patients with hemophilia A/B with inhibitors. A growing literature suggests that there may be expanded indications for the use of NovoSeven in patients with significant bleeding who do not have a known factor deficiency. Severe bleeding refractory to standard hematologic or hemostatic support is common in patients undergoing bone marrow transplantation (BMT). We review our experience with rFVIIa in three patients (8 years 8 months to 19 years, median 13 years) treated for pulmonary hemorrhage (n ‫؍‬ 1), hemorrhagic cystitis (n ‫؍‬ 3), and gastrointestinal bleeding (n ‫؍‬ 2). Boluses of 90-270 g/kg rVIIa with subsequent doses of 90 g/kg every 4-24 h for 3-14 days were given, concurrent with maintaining platelet counts Ͼ50 000/mm 3 . Transient clinical responses in gross hematuria (two patients) and in pulmonary hemorrhage were noted within several days of starting rFVIIa, but bleeding in a new site in two patients and renewed bleeding of the initial site in the third resulted in discontinuation of the drug. No toxicity or adverse events were observed while the patients were on rFVIIa treatment. Because of the substantial cost of this product, the lack of adequate monitoring methodology, and the variability of current dose and dosing intervals, large randomized studies are needed before definitive off-label use in the setting of BMT can be recommended. Bone Marrow Transplantation (2001) 28, 405-407. 
Novo Nordisk Pharmaceuticals, Princeton, NJ, USA). Its approved or labeled use is for bleeding in patients with hemophilia A/B who have anti-factor VIII or IX antibodies (where its presumed mechanism of action is to complex with tissue factor and activate factor X, thus bypassing factors VIII and IX). 1 That rFVIIa binds in vitro with low affinity to activated platelet surfaces and, independently of tissue factor, induces the thrombin burst needed for hemostasis 2 has suggested a range of other potential clinical uses for the drug. In addition there is a growing body of clinical evidence that rFVIIa is efficacious in the treatment of bleeding associated with thrombocytopenia, with shortening of the bleeding time in 50% of patients treated.
3 A single report of an adult with acute myelogenous leukemia and acquired factor VII deficiency secondary to pulmonary aspergillosis has suggested that rFVIIa may be useful for the management of pulmonary hemorrhage. 4 Severe bleeding refractory to standard hematologic and hemostatic support is common in patients undergoing bone marrow transplantation (BMT). We report our preliminary experience with rFVIIa in patients with intractable bleeding undergoing BMT.
Patients and methods

Patients
All patients on the BMT service who had received rFVIIa between April 1999 (when the drug first became available at the University of North Carolina Hospitals) and 1 November 2000 were identified through the hospital's pharmacy records. Consent was obtained from the Institutional Review Board and medical records were reviewed retrospectively for patient demographics (age, gender, primary diagnosis), history of bleeding diatheses, indications for rFVIIa, and outcome of bleeding episodes. The cost of rFVIIa therapy to the hospital was established by review of Department of Pharmacy accounting records.
Administration of rFVIIa and evaluation of response
Although no formal protocol was followed, use of rFVIIa was limited to patients for whom all other more conventional hematological and hemostatic support was felt to have been exhausted. Patients had responded incompletely or not at all to a variety of therapeutic modalities including maintenance of platelet counts above 50 000/mm 3 , infusions of fresh frozen plasma, intravesicular administration of prostaglandins for hemorrhagic cystitis, high-dose corticosteroids for pulmonary hemorrhage, epsilon aminocaproic acid, or to intravenous administration of desmopressin (DDAVP) where uremia was thought to be a contributing factor . Many of these supportive measures were continued during rFVIIa administration, including platelet infusions to maintain platelet counts Ͼ50 000/mm 3 and to provide low affinity platelet binding sites. Boluses of rFVIIa (90-270 g/kg) with subsequent doses of 90 g/kg every 4-24 h for 3-14 days were given with an intent to maintain prothrombin times Ͻ10 s. Novo Seven was discontinued when bleeding became progressive. Responses, based subjectively on daily clinical notes in the medical records and on changes in ongoing transfusion requirements, were rated as partial or no response.
Results
Three patients were identified who had received rFVIIa at our institution during an admission for BMT. As shown in Table 1 , two patients had undergone matched unrelated donor transplants and one an allosibling matched transplant for diagnoses of progressive AML, secondary AML, and aplastic anemia. Ages were 8 years 8 months, 13 and 19 years; all were female. Initial indications for rFVIIa were pulmonary hemorrhage documented radiographically and by bronchoscopy (patient 1), severe hemorrhagic cystitis demonstrated sonographically and by cystoscopy (patients 1-3), and gross lower gastrointestinal (GI) bleeding confirmed endoscopically (patients 1 and 3). Bleeding was diffuse without focal bleeding points in all patients. No patient had evidence of disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, or prior bleeding diathesis such as von Willebrand's disease (by history or pretransplant measurements of prothrombin and partial thromboplastin times).
As shown in Table 2 , patient 1 had a transient decrease both in gross hematuria and pulmonary hemorrhage with decreased oxygen requirements and hemoptysis, following 4 days of rFVIIa and ongoing platelet and FFP infusions. However, in the face of ongoing rFVIIa (90 g/kg every 6 h), she developed a massive lower GI hemorrhage and 
Discussion
In this small retrospective series, three patients received treatment with rFVIIa for profuse bleeding unresponsive to more conventional measures. In all cases, infusions of platelets and fresh frozen plasma were thought to have been optimized prior to initiation of rFVIIa and infusions of these products were continued during rFVIIa administration. In particular, platelet transfusions were continued in an effort to provide binding sites for rVIIa. Although the use of rFVIIa was not protocol-driven and was neither blinded nor placebo-randomized, decreased bleeding temporarily related to product administration was reported in two or three patients. Two of the three patients with hemorrhagic cystitis had transient but clear diminution of bleeding following administration of rFVIIa, and one of these patients also had a partial response of her pulmonary hemorrhage. In both cases, responses were not observed for several days so that they could not unequivocally be attributed to rFVIIa. In both cases multiple new sites of bleeding developed on therapy. The third patient, who received rFVIIa only on a daily basis, had no improvement in her gross hematuria. Consistent with prior experience, rFVIIa was well-tolerated by our patients. Although hypersensitivity reactions (pruritis, rash, fever, nausea, headache, vomiting), full-blown anaphylaxis, and thromboembolic events rarely have been described, 5 no such episodes were noted. The major dose-limiting factor was cost, which was as high as $200 000 for a 16-day trial.
Immediate and permanent response of pulmonary hemorrhage to rFVIIa (90 g/kg every 2 h for two doses, daily for 2 days) has been reported in a 40-year-old man with AML and aspergillosis-related acquired factor VII deficiency. 4 In contrast, none of our patients, whose pro-thrombin times had been normalized with FFP infusions, was thought to be deficient in factor VII at the time rFVIIa was initiated. Anecdotal reports support the efficacy of rVIIa in the treatment of bleeding due to congenital and acquired platelet dysfunction, 6,7 liver failure, 8 and in uncontrolled intraoperative bleeding. 8 In these clinical settings, both high affinity binding to tissue factor (exposed by mucosal damage) and low-affinity, non-tissue factor dependent binding to activated platelet surfaces with induction of the thrombin burst needed for hemostasis, were advanced as likely mechanisms of action. These encouraging results obtained late in the course of bleeding episodes suggest that the use of rFVIIa for severe mucosal bleeding in the setting of bone marrow transplantation, even in patients without acquired factor VII deficiency, deserves further evaluation. Several large randomized trials have been initiated.
